Stroke Outcomes in the COMPASS Trial | Zendy

Mukul Sharma | Zendy; Robert G. Hart | Zendy; Stuart J. Connolly | Zendy; Jackie Bosch | Zendy; Olga Shestakovska | Zendy; Kelvin Kuan Huei Ng | Zendy; Luciana Catanese | Zendy; Katalin Keltai | Zendy; Victor Aboyans | Zendy; Marco Alings | Zendy; JongWon Ha | Zendy; George Varigos | Zendy; Andrew Tonkin | Zendy; Martin O’Donnell | Zendy; Deepak L. Bhatt | Zendy; Keith A.A. Fox | Zendy; Aldo P. Maggioni | Zendy; Scott D. Berkowitz | Zendy; Nancy Cook Bruns | Zendy; Salim Yusuf | Zendy; John W. Eikelboom | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stroke Outcomes in the COMPASS Trial

Author(s) -

Mukul Sharma,

Robert G. Hart,

Stuart J. Connolly,

Jackie Bosch,

Olga Shestakovska,

Kelvin Kuan Huei Ng,

Luciana Catanese,

Katalin Keltai,

Victor Aboyans,

Marco Alings,

JongWon Ha,

George Varigos,

Andrew Tonkin,

Martin O’Donnell,

Deepak L. Bhatt,

Keith A.A. Fox,

Aldo P. Maggioni,

Scott D. Berkowitz,

Nancy Cook Bruns,

Salim Yusuf,

John W. Eikelboom

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.035864

Subject(s) - medicine , aspirin , rivaroxaban , stroke (engine) , hazard ratio , modified rankin scale , coronary artery disease , intracerebral hemorrhage , warfarin , randomized controlled trial , anesthesia , cardiology , surgery , atrial fibrillation , confidence interval , ischemic stroke , subarachnoid hemorrhage , mechanical engineering , ischemia , engineering

Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies). We present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research